

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 691 406 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
10.01.1996 Bulletin 1996/02

(51) Int. Cl.<sup>6</sup>: **C12N 15/53**, C12N 15/73,  
C12N 9/02

(21) Application number: **95114069.8**

(22) Date of filing: **03.07.1984**

(84) Designated Contracting States:  
**AT BE CH DE FR GB IT LI NL SE**

(30) Priority: **15.07.1983 US 514188**

(62) Application number of the earlier application in  
accordance with Art. 76 EPC: **88121246.8**

(71) Applicant **BIO-TECHNOLOGY GENERAL  
CORPORATION**  
**New York New York 10017 (US)**

(72) Inventors:  
• **Aviv, Haim**  
**Rehovot (IL)**  
• **Gorecki, Marian**  
**Rehovot (IL)**

- **Levanon, Avigdor**  
**Netania (IL)**
- **Oppenheim, Amos**  
**Ramat Sharet, Jerusalem (IL)**
- **Vogel, Tikva**  
**Rehovot (IL)**
- **Zeelon, Elisha**  
**Moshav Mishmar, Hashiva (IL)**
- **Zeevi, Menachem**  
**Ramat Gan (IL)**

(74) Representative: **Henkel, Feiler, Hänzel & Partner**  
**D-81675 München (DE)**

Remarks:

This application was filed on 07 - 09 - 1995 as a  
divisional application to the application mentioned  
under INID code 60.

(54) **Process for the preparation of superoxide dismutase by recombinant DNA-technology**

(57) Disclosed is an improved plasmid which upon  
introduction into a suitable *Escherichia coli* host cell con-  
taining the thermolabile repressor  $C_{11}$ , renders the host  
cell capable, upon increasing the temperature of the host  
cell to a temperature at which the repressor is destroyed,  
of effecting expression of a gene encoding superoxide  
dismutase inserted into the vector, and production of the  
superoxide dismutase encoded by the gene.

**EP 0 691 406 A1**

## Description

## BACKGROUND OF THE INVENTION

One aspect of genetic engineering involves the insertion of foreign DNA sequences derived from eukaryotic sources into *Escherichia coli* or other microorganisms. A further refinement of genetic engineering concerns inducing the resulting microorganism to produce polypeptides encoded by the foreign DNA. Production of polypeptides can be considered a two-step process, with each step including numerous substeps. The two steps are transcription and translation. To produce a polypeptide efficiently and in quantity both steps of the process must be efficient. Transcription is the production of mRNA from the gene (DNA). Translation is the production of polypeptide from the mRNA.

A critical substep of the transcription process is initiation, that is, the binding of RNA polymerase to a promoter-operator region. The sequence of deoxyribonucleotide bases which make up the promoter region may vary and thereby effect the relative efficiency of the promoter. The efficiency depends on the affinity of the RNA polymerase for the promoter.

The efficiency of translation is affected by the stability of the mRNA. Increased stability of the mRNA permits improved translation. Although the exact determinants of mRNA stability are not precisely known, it is known that mRNA secondary structure as determined by the sequence of its bases has a role in stability.

The initial substep of translation involves binding of the ribosome to a base sequence on the mRNA known as the Shine-Dalgarno sequence or the ribosomal binding site (RBS). The synthesis of polypeptides begins when the ribosome migrates along the mRNA to the AUG start codon for translation. Generally these codons are found approximately 10 bases "downstream" from the Shine-Dalgarno site. Factors which increase the efficiency of translation include those which enhance binding of the ribosomes to the Shine-Dalgarno site. It has been shown that the secondary structure of the mRNA in the region of the Shine-Dalgarno sequence and the AUG codon and the distance between the Shine-Dalgarno sequence and the AUG codon each play a critical role in determining the efficiency of translation. Other factors which affect the efficiency of translation are premature termination and attenuation. Efficiency of translation can be improved by removing the attenuation sites.

A difficulty encountered in attempts to produce high amounts of eukaryotic polypeptides in bacterial cells involves the inability of cells producing large amounts of mRNA to grow efficiently. This difficulty can be eliminated by preventing transcription by a process known as repression. In repression genes are switched off due to the action of a protein inhibitor (repressor protein) which prevents transcription by binding to the operator region. After microorganisms have grown to desired cell densities, the repressed genes are activated by destruction of the repressor or by addition of molecules known as inducers which overcome the effect of the repressor.

Numerous reports may be found in the literature concerning the cloning of eucaryotic genes in plasmids containing the  $P_L$  promoter from  $\lambda$  bacteriophage. (Bernard, H.V. et al., Gene (1979) 5, 59; Derom, C. et al., Gene (1982) 17, 45; Gheysen, D. et al., Gene (1982) 17, 55; Hedgpeth, J. et al., Mol. Gen. Genet. (1978) 163, 197; Remaut, E. et al., (1981) Gene 15, 81; and Derynck, R., et al., Nature (1980) 287, 193. In addition, European Patent Application No. 041.767, published December 16, 1981 describes expression vectors containing the  $P_L$  promoter from  $\lambda$  bacteriophage. However, none of these references describe the use of the  $C_{II}$  ribosomal binding site.

The use of a vector containing the  $P_L$  promoter from  $\lambda$  bacteriophage and the  $C_{II}$  ribosomal binding site has been described. (Oppenheim, A.B. et al., J. Mol. Biol. (1982) 158, 327 and Shimatake, H. and Rosenberg, M., Nature (1981) 292, 128.) These publications describe the production of increased levels of  $C_{II}$  protein but do not involve or describe the production of eucaryotic proteins.

In 1982 Shatzman and Rosenberg presented a poster at the 14th Miami Winter Symposium (Shatzman, A.R. and Rosenberg, M., 14 Miami Winter Symposium, abstract p98 [1982]). This abstract provides a non-enabling disclosure of the use of a vector containing  $P_L$  from  $\lambda$  bacteriophage, Nut and the  $C_{II}$  ribosomal binding site to synthesize a "eucaryotic" polypeptide (SV40 small T antigen is actually not a eucaryotic polypeptide but a viral protein) in an amount greater than 5% of the cell protein in an unnamed bacterial host. The operator used is not defined. Neither an origin of replication nor a gene for a selectable phenotype is identified. This system with which the vector is used is described as including certain host lysogens into which the vector can be stably transformed. The present invention in one embodiment, i.e., pMG100, may have certain similarities to this vector. However, it is not transformed into a host lysogen, but rather into suitable *E. coli* host strains which contain the thermolabile repressor  $C_I$  and the N gene but from which the rest of the lysogen has been removed. Moreover, it has been employed to produce bGH and hGH analogs in amounts in excess of 20% of total cell protein.

In addition, in other embodiments of this invention ribosomal binding sites which differ from  $C_{II}$  are employed. Also, in the presently most preferred vectors, pND5 and its derivatives, nonessential sequences have been removed to create a vector permitting polypeptide production in amounts which are more than 10% greater than those obtained with pMG100.

Recently, applicants have learned of the existence of a pending U.S. patent application in the name of M. Rosenberg filed under Serial No. 457,352 by the National Institutes of Health, Dept. of Health and Human Services, U.S.A. Portions

of this application have been obtained from the National Technical Information Service, U.S. Dept. of Commerce. However, the claims are not available and are maintained in confidence. The available portions of the application have been reviewed. This disclosure is not enabling. It indicates that the host is important (p8, line 17) but fails to identify any suitable host. It further depends upon the use of a  $\lambda$  mutant which is not specified (p4, line 20). It indicates that the host contains lysogens (p8, line 18) unlike the present invention in which the host is not lysogenic. It mentions cloning and expression of a eucaryotic gene, monkey metallothionein gene, (p7, line 18) but does not provide details. It specifies that neither the sequence nor the position of any nucleotide in the  $C_{II}$  ribosomal binding region has been altered. (p3, line 27) In the present invention such alteration is possible

No disclosure is present in the art concerning: successful expression with a  $P_L$ - $C_{II}$  containing vector system of bovine or human growth hormones; production of bGH or hGH analogs having biological activity; compositions containing such analogs or uses of them; or induction methods for achieving polypeptide production in amounts greater than 20% of the total protein produced by the host.

The only disclosure in the art concerning production of bGH, analogs by hosts transformed with genetically engineered vectors involves the use of the Trp promoter to produce a bGH analog having the amino acid Met at the N-terminus of the phenylalanine form of natural bGH (Seeburg, P.H. et al., DNA (1983) 2, 37.

The only disclosure in the art concerning production of hGH analogs by hosts transformed with genetically engineered vectors involves the use of the Lac and Trps promoters to produce an analog of hGH having the amino acid Met at the N-terminus of the natural hGH. (Goedell, D.V. et al., Nature (1979) 281, 544)

## SUMMARY OF THE INVENTION

This invention concerns an improved expression vector which upon introduction into a suitable bacterial host cell, namely, *Escherichia coli*, containing the thermolabile repressor  $C_I$  renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of the polypeptide encoded by the gene comprising:

a double-stranded DNA molecule which includes in 5' to 3' order the following:  
a DNA sequence which contains the promoter and operator  $P_L O_L$  from lambda bacteriophage;  
the N utilization site for binding antiterminator N protein produced by the host cell;  
a DNA sequence which contains a ribosomal binding site for rendering the mRNA of the desired gene capable of binding to ribosomes within the host cell;  
an ATG initiation codon or a DNA sequence which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; and  
a restriction enzyme site for inserting the desired gene into the vector in phase with the ATG initiation codon;  
and which additionally includes a DNA sequence which contains an origin of replication from a bacterial plasmid capable of autonomous replication in the host cell and a DNA sequence which contains a gene associated with a selectable or identifiable phenotypic trait which is manifested when the vector is present in the host cell. Preferred vectors are pMG 100 and pND5.

Genes, i.e., cDNAs, encoding desired polypeptides such as growth hormones, e.g., bovine, porcine, chicken or human growth hormones, superoxide dismutase, apoprotein E, viral protein I of foot and mouth disease virus, protein A from *S. aureus*, interleukin III, an enzyme or analogs thereof may be inserted into the restriction enzyme site of the vector to create plasmids. The plasmids in turn can be introduced into suitable hosts where the genes can be expressed and the desired polypeptide produced. Preferred plasmids for bGH are pRec 2/3 and pROI; and for hGH, pTV 18(1) and pTV 104(2). Suitable hosts include *Escherichia coli* A1637, A1645, A2602 and A1563; A1637 being presently preferred.

The resulting host vector systems can be employed to manufacture polypeptides. The host cells containing the plasmids are grown under suitable conditions permitting production of polypeptide and the resulting polypeptide is recovered. Presently preferred conditions involve growth at about 42°C for 10 to 30 minutes, particularly 15 minutes, followed by continued growth at about 37-39°C for sufficient time to make the total growth period about 60-90 minutes, particularly growth at 38-39°C for about 75 minutes. Presently preferred growth media are lactalbumin hydrolysate with addition of glucose or brain heart infusion.

Using the host-vector systems, analogs of bGH and hGH have been prepared. These analogs may be incorporated into veterinary or pharmaceutical compositions, respectively.

The respective analogs directly, or in such compositions, may be used to stimulate milk or meat production in a bovine or to treat human growth hormone deficiency.

## DESCRIPTION OF THE FIGURES

FIG. 1. Construction of pMG100 expression vector. This plasmid was built by inserting a fragment of  $\lambda$  phage DNA contained between restriction sites *Hae*III (location 38150) and *Sau*3A (location 38362) into a pKC30 plasmid DNA

cleaved with HpaI and BamHI. The HaeIII-Sau3a fragment carries  $\text{nut}_L$ ,  $t_{RI}$ ,  $\text{cy}^-$  and ribosomal binding site of  $C_{II}$  protein ( $C_{II}$ -RBS). Subcloning of the  $C_{II}$ -RBS containing DNA into pKC30 creates pMG100 which contains a unique BamHI restriction site right after the ATG initiation codon of  $C_{II}$ -RBS and an NdeI restriction site within the ATG triplet (bottom inset). Numbers in parentheses denote location of restriction sites on the  $\lambda$  phage DNA.

FIG. 2. Construction of pRec 2/3 plasmid. A bGH cDNA containing plasmid, D<sub>4</sub>, was digested with HaeII. A resulting 1600 bp large fragment was purified and subjected to digestion at 37°C for 5 minutes with 5 units of SI exonuclease. A synthetic EcoRI linker with the sequence:

GGAATTCC

CCTTAAGG

was attached by ligation. The product was cleaved with EcoRI and inserted into pBR322 which had been cleaved with EcoRI. A clone, pALRI, was isolated which upon cleavage with EcoRI released a 1200 bp fragment with the sequence:

AATTCCTCA . . . .

GGGT . . . .

at the 5' end. Formation of this sequence demonstrates that pALRI contains an EcoRI restriction site which includes the TTC codon for residue number 1 (phenylalanine) of authentic bGH. pALRI was subjected to a partial cleavage with PstI. The digest was ligated with HindIII linkers and cleaved with EcoRI and HindIII. The fragment containing bGH cDNA was isolated and subcloned into pBR322 between EcoRI and HindIII restriction sites to give pAL500. The sub-cloned bGH cDNA fragment was then excised from pAL500 with EcoRI and HindIII, "filled in" with DNA polymerase "Klenow" fragment and inserted into the pMG100 expression vector (FIG. 1) opened at the BamHI site and also "filled in" as above. The resulting vector pREC 2/2, expresses a modified bGH which is altered at its amino terminus as follows:

MetAspGlnPhe<sup>1</sup>Pro<sup>2</sup>.....bGH

The plasmid pREC 2/2 was digested with PstI and the fragment containing the  $P_L$  promoter and the 5' end of the bGH gene (designated fragment A) was isolated. This fragment was ligated to a PstI fragment from pAL 500 (designated fragment B). The then resulting vector, pRec 2/3, expresses a modified bGH which is altered at its amino terminus as follows:

MetAspGlnPhe<sup>1</sup>Pro<sup>2</sup>.....bGH

FIG. 3. Construction of expression vectors pND5, pND55 and pROI. A plasmid pOG7 (A. Oppenheim, S. Gottesman and M. Gottesman, J. Mol. Biol. (1982) 158, 327) was cleaved with NdeI. The ends of the large fragment carrying the  $P_L$  promoter  $\text{nut}_L$ ,  $t_{RI}$  and  $C_{II}$ -RBS were ligated to give the pND5 expression vector. This pND5 vector DNA is opened with NdeI. Insertion of that NdeI fragment from pRec 2/3 (FIG. 2) which contains bGH cDNA results in a plasmid pROI which appears to be a better expressor of the modified bGH described in FIG. 2 than pRec 2/3. Insertion of synthetic linkers with the sequence:

TATGAGCTCA

ACTCGAGTAT

into pOG7 cleaved with NdeI results in an expression vector pND55 which contains a unique SacI restriction site in front of ATG. When pND55 is cleaved with SacI and treated with DNA polymerase "Klenow" fragment an ATG initiation codon results which follows the  $P_L$  promoter and  $C_{II}$ -RBS. This vector is suitable for expression of a wide variety of eukaryotic genes lacking an ATG initiation codon.

FIG. 4 Construction of pTV 18(1) and pTV 104(2). A plasmid, pTVHGH was prepared by cloning cDNA encoding hGH into the HindIII site of pBR 322 using standard methods. Meth. Enzymol. (1979) 68, 75. This plasmid was digested with HindIII. The resulting 800 base pair fragment was purified and further digested with FnuDII and "filled in" with DNA polymerase "Klenow" fragment. This treatment removes codons for the first 16 amino acids of hGH. The resulting DNA fragment is ligated with a synthetic linker which restores the codons for the sequence of hGH from Met<sup>14</sup> and regenerates an NdeI restriction site in front of the ATG codon for Met<sup>14</sup>. After treatment with NdeI this semi-synthetic DNA was inserted into the pND5 vector opened with NdeI. The resulting plasmid pTV 18(1)

expresses hGH under control of the P<sub>L</sub> promoter. This hGH is an analog missing the first 13 amino acid residues and having at its N-terminus Met<sup>14</sup>.

Plasmid pTV 18(1) was partially digested with NdeI and ligated with a synthetic linker which contains the codons for amino acids 1-13 of hGH:

TATGTTCCCAACCATTCATTATCCCGTCTGTTGACAAACGC  
ACAAGGGTTGGTAAGGTAATAGGGCAGACAAGCTGTTGCGAT.

The linker is also complementary to the NdeI site on pTV 18(1) and positions the complete hGH gene in phase with the ATG initiation codon of the pND5 expression vector (FIG. 3). Thus, the resulting plasmid, pTV 104(2), expresses native hGH with an extra methionine at the N-terminus.

FIG. 5 shows the vector pAL Trp 46 which contains the Trp promoter and the first seven amino acids of the Trp E gene transcriptionally fused to the  $\beta$ -galactosidase gene.

FIGS. 6, 7 and 8 show a series of expression vectors (Tac) containing a part of the Trp promoter and Lac operator followed by restriction sites for insertion of a desired gene and expression of bGH under the control of Tac promoter.

FIGS. 9 and 10 show expression vectors containing bGH cDNA under the control of the histidine promoter.

FIG. 11 shows insertion of the bGH gene into an expression vector under the control of the Lac promoter.

FIG. 12 shows expression of bGH gene under control of Omp F promoter.

FIG. 13. Construction of Met<sup>4</sup>-bGH analog pAL401 and expression vectors pND6 and pND11 with altered restriction sites:

pAL401 which expresses a modified form of bGH which is lacking the first three amino acids at the amino terminus of the bGH (Met<sup>4</sup> bGH) was constructed by triple ligation of the following:

- a) a bGH DNA fragment of 623 base pairs with PvuII and HindIII excised from pAL500
- b) a linker formed by synthesizing two DNA strands which after purification were annealed to form:

CCATATGTCCTTGTCCGGCTGTCTTGCACACGCTGTGCT  
GCGACACGAGCCCGAGTGTGCACTGGTGCACG

which was "filled in" with DNA polymerase "Klenow" fragment and then cleaved with NdeI and PvuII to prepare a 58 base pair fragment which was recovered and purified.

c) pND11 which was prepared as follows. An expression vector pOG7 was altered by elimination of HindIII and one of the NdeI sites (distant from the ATG initiator codon) to obtain pND6. Then HindIII linkers were introduced into a SalI site to give pND11.

FIG. 14. Construction of authentic bGH modified with methionine at the amino terminus and various analogs of bGH.

a) Plasmid pAL401 is treated with NdeI. A synthetic DNA linker containing an ATG initiation signal and the code for the first three amino acids at the amino terminus of native bGH is ligated into the NdeI site. The resulting vector pAL601 leads to the expression of native bGH containing an extra methionine residue at the amino terminus.

b) Using the strategy described in a) but modifying the structure of the oligodeoxyribonucleotide linker a class of vectors coding for a series of modified bovine growth hormones is constructed. The modified growth hormones start with methionine at the N-terminus and are followed by any of the twenty naturally occurring amino acids in each of positions 1 and 2, and any of the twenty amino acids other than Glu, Gln, Lys, Met or Trp in position 3. Proceeding from position 4 to the COOH-terminus the sequence is identical to that of native bGH.

FIG. 15. Tibia test. This figure shows the comparison between effect of pRec 2/3 bGH analog and authentic bGH on the bone plate growth of hypophysectomized rats.

#### DETAILED DESCRIPTION OF THE INVENTION

A vector has been developed which enables the achievement of enhanced levels of gene expression and polypeptide expression. The vector is a double-stranded DNA molecule. Upon introduction into a suitable bacterial host cell containing the thermolabile repressor  $C_1$  and increasing the temperature of the host to a temperature at which the repressor is destroyed, the vector renders the host cell capable of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene.

The vector includes in 5' to 3' order the following:

- a DNA sequence which contains the promoter and operator  $P_{O_L}$  from lambda bacteriophage;
- the N utilization site for binding antiterminator N protein produced by the host cell;
- a DNA sequence which contains a ribosomal binding site for rendering the mRNA of the desired gene capable of binding to ribosomes within the host cell;
- an ATG initiation codon or a DNA sequence which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; and
- a restriction enzyme site for inserting the desired gene into the vector in phase with the ATG initiation codon.

The vector also includes a DNA sequence which contains an origin of replication from a bacterial plasmid capable of autonomous replication in the host cell and a DNA sequence which contains a gene associated with a selectable or identifiable phenotypic trait which is manifested when the vector is present in the host cell.

The host for use with the vector is *Escherichia coli*. The presently preferred strains are A1637, A1645, A2602 and A1563. A1637 is presently the most preferred strain. It was obtained from C600 by inserting transposon containing tetracycline resistance gene within the galactose operon as well as the lambda system for expression which is close to galactose operon. It has been deposited with the American Type Culture Collection in Rockville, Maryland, U.S.A. containing various plasmids as described more fully hereinafter. All such deposits were made pursuant to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms.

A1645 was obtained from A1637 by selection for Gal<sup>+</sup> (ability to ferment galactose) as well as loss of tetracycline resistance. It still contains the lambda expression system but part of the transposon has been removed by selection. Its phenotype is C600  $r^{-}m^{-}gal^{+}thr^{-}leu^{-}lacZ^{-}$  ( $\lambda$ C1857  $\Delta$  HI  $\Delta$  BAM N+).

A2602 and A1563 are derived from SA500. Their phenotypes are SA500  $his^{-}ilu^{-}gal^{+} \Delta$  8 ( $\lambda$ C1857  $\Delta$  HI  $\Delta$  BAM N+ and SA500  $his^{-}ilu^{-}gal^{+} \Delta$  8  $lacZx$ A21 ( $\lambda$ C1859 int2 xis1 nutL3  $\Delta$  HI), respectively.

Preferably the vector is a covalently closed circular double-stranded molecule. However, it is not essential that the vector be covalently closed.

The vector achieves its enhanced expression levels after the host cell is heated to a temperature at which the  $C_1$  repressor is destroyed. A temperature above about 42°C is effective for this purpose and since it is desired that unnecessary heat damage to the host cells be avoided to as great an extent as possible, it is generally desirable that the temperature never exceed 42°C by more than a few degrees.

One important component of the vector is the ribosomal binding site. Suitable sites are  $C_{II}$  from lambda bacteriophage having the sequence:

TAAGGAATACTTACAT

ATTCCTTTATGAATGTA;

a synthetic oligonucleotide having the sequence:

TAAGGAAGTACTTACAT

ATTCCTTCATGAATGTA; and

the major head protein gene of bacteriophage lambda having the sequence

TTTTTTTACGGGATTTTTTTATG

AAAAAATGCCCTAAAAAATAC.

Another component of the vector is the restriction enzyme site for insertion of desired genes into the vector in phase with the ATG initiation codon. Numerous such sites may be used. The presently preferred sites are BamHI, SacI and NdeI.

The vector also includes an origin of replication from a bacterial plasmid capable of autonomous replication in the host cell. Suitable such origins of replication may be obtained from a number of sources. Presently preferred are origins of replication derived from pBR322 or pRI.

A DNA sequence which contains a gene associated with a selectable or identifiable phenotypic trait which is manifested when the vector is present in the host cell is also a component of the vector. Suitable genes include those associated with temperature sensitivity or drug resistance, e.g., resistance to ampicillin, chloramphenicol or tetracycline.

Relative to vectors previously described in the scientific literature, the vectors of this invention may be used to obtain enhanced expression of a wide variety of genes encoding desirable polypeptide products. Suitable genes include those encoding growth hormones, e.g., bovine, porcine, chicken or human growth hormones; superoxide dismutase; apopro-

tein E; viral protein I of foot and mouth disease virus, protease A from *S. aureus*, interleukin III, enzymes, or analogs of any of the preceding. By analog is meant a polypeptide having the same activity as the naturally occurring polypeptide but having one or more different amino acids at the N-terminus of the polypeptide.

The vector may be formed by methods well known to those skilled in the art to which the invention relates. Such methods are described in greater detail in various publications identified herein, the contents of which are hereby incorporated by reference into the present disclosure in order to provide complete information concerning the state of the art.

One presently preferred vector is pMG100 having the restriction map shown in FIG. 1. This vector has had cDNA encoding bovine growth hormone inserted into its *Bam*HI restriction site. The resulting plasmid is designated pRec 2/3 bGH. Its restriction map is shown in FIG. 2. The plasmid pRec 2/3 bGH was introduced into *Escherichia coli* strain A1637 using conventional transformation methods. The resulting host vector system has been deposited under ATCC No. 39385.

A second presently preferred vector is pND5 having the restriction map shown in FIG. 3. Bovine growth hormone cDNA has been inserted into its *Nde*I restriction site. The resulting plasmid is designated pROI. Its restriction map is also shown in FIG. 3. The plasmid pROI was introduced into *E. coli* strain A1637 via transformation. The host vector system which resulted has been deposited under ATCC No. 39390.

The vector pND5 has also been used to clone human growth hormone. One plasmid designated pTV 18(1) and another designated pTV 104(2) have been created by inserting hGH cDNA into the *Nde*I restriction sites. pTV 18(1) is shown in FIG. 4. It has been introduced into *E. coli* strain A1637 via transformation. The resulting host vector system has been deposited under ATCC No. 39386. pTV 104(2) is shown in FIG. 4. It also has been introduced into *E. coli* strain A1637. The resulting host vector system has been deposited under ATCC No. 39384.

Using the same approach other plasmids may be prepared by inserting into the restriction enzyme site of a vector of the invention a gene encoding a desired polypeptide.

The preceding specific host vector systems involve *E. coli* A1637. However, as previously indicated other strains have been used including A1645, A2606 and A1563. These host vector systems may be used to produce polypeptides such as bovine and human growth hormones. To do so the host vector system is grown under suitable conditions permitting production of the polypeptide which is then recovered.

Suitable conditions involve growth of the host vector system for an appropriate period of time at about 42°C followed by continued growth at about 37-39°C for an additional period of time, the growth being carried out on a suitable medium.

Desirably the initial period of growth is about 10 to 30 minutes at 42°C followed by growth at 37-39°C for a sufficient period of time such that the total period of growth is about 60 to 90 minutes. Preferably the growth is for about 15 minutes at 42°C followed by about 75 minutes at 38-39°C. Suitable media include lactalbumin hydrolysate with addition of glucose and brain heart infusion. In order to stably maintain the vector in the host it is critical that the host be maintained under selective pressure, e.g., addition of antibiotic.

By means of the preceding method a number of bGH and hGH analogs has been prepared. These have or may have the activity of the naturally occurring hormones.

bGH analogs have the activity of natural bGH and an identical amino acid sequence except for variations at the N-terminus of up to five (5) amino acids. Examples include the following:

- 1) amino acid methionine added to N-terminus of the phenylalanine form of bGH.
- 2) amino acid methionine added to N-terminus of the alanine form of bGH.
- 3) amino acid sequence Met-Asp-Gln added to N-terminus of the phenylalanine form of bGH.
- 4) amino acid sequence Ala-Gly added to N-terminus of the alanine form of bGH.
- 5) amino acid sequence Met-Gly added to N-terminus of the alanine form of bGH.
- 6) amino acid sequence Met-Asp-Pro-Met-Gly added to N-terminus of the alanine form of bGH.
- 7) amino acid sequence Met-Asp-Pro added to N-terminus of the phenylalanine form of bGH.
- 8) amino acid sequence Met-Thr-Arg added to N-terminus of the phenylalanine form of bGH.
- 9) amino acids up to methionine (4 position) removed from N-terminus of phenylalanine form of bGH.

And analog of bGH having the amino acid sequence:

Met-(X)<sub>n</sub>-Y-Met...

wherein Met is the N-terminus, X is any of the twenty naturally occurring amino acids, Y is any of the twenty amino acids

other than Glu, Gln, Lys, Met or Trp, n is an integer from 0 to 6 and Met... is the sequence of natural bGH from position 4 to the COOH-terminus (position 191).

hGH analogs have the activity of natural hGH and an identical amino acid sequence except for variations at the N-terminus. Examples include the following:

- 1) amino acid methionine added to N-terminus of natural hGH.
- 2) amino acids up to methionine (14 position) removed from N-terminus of hGH.

An analog of hGH having the amino acid sequence:

Met-(X)<sub>n</sub>-Y-Met...

wherein Met is the N-terminus, X is any of the twenty naturally occurring amino acids, Y is any of the twenty amino acids other than Glu, Gln, Lys, Met or Trp, n is an integer from 0 to 13 and Met... is the sequence of natural hGH from position 14 to the COOH-terminus (position 191).

Veterinary compositions may be prepared which contain effective amounts of one or more bGH analog and a suitable carrier. Such carriers are well-known to those skilled in the art. The analogs may be administered directly for in the form of a composition to a bovine in order to increase milk or meat production.

Pharmaceutical compositions may be prepared which contain effective amounts of one or more hGH analog and a suitable carrier. Such carriers are well-known to those skilled in the art. The analogs may be administered directly or in the form of a composition to a human subject, e.g., one afflicted by dwarfism, to treat deficiencies in hGH production by the subject.

#### EXAMPLES

The examples which follow are set forth to aid in understanding the invention but are not intended to, and should not be so construed as to, limit its scope in any way. The examples do not include detailed descriptions for conventional methods employed in the construction of vectors, the insertion of genes encoding polypeptides of interest into such vectors or the introduction of the resulting plasmids into bacterial hosts. Such methods are well-known to those skilled in the art and are described in numerous publications including the following:

Principles of Gene Manipulation, An Introduction to Genetic Engineering, 2nd Edition, edited by R.W. Old and S.B. Primrose, Univ. of Calif. Press (1981)

Met. Enzymol. vol. 68, Recombinant DNA, edited by Ray Wu.

Met. Enzymol. vol. 65, Nucleic Acids (Part 1), edited by Lawrence Grossman and Kivie Moldave

T. Maniatis, E.F. Fritsch and J. Sambrook, Molecular Cloning; A Laboratory Manual, Cold Spring Harbor Laboratory, NY (1982)

H.V. Bernard et al., Gene (1979) 5, 59

A.B. Oppenheim et al., J. Mol. Biol. (1982) 158, 327

E. Remaut et al., Gene (1981) 15, 81

#### EXAMPLE 1

#### EXPRESSION VECTORS

As used herein the term expression vector refers to a group of plasmids useful for expressing desired genes in bacteria, particularly in *E. coli*. The desired gene may be inserted into the expression vector or alternatively, the promoters on the expression vector may be excised and placed in front of the desired gene.

#### I. P<sub>L</sub> EXPRESSION VECTORS

##### A. pMG 100

pMG 100, as shown in FIG. 1 and described in detail under Description of the Figures is composed of  $\lambda$  DNA inserted into the multicopy plasmid pBR322. The salient features of the  $\lambda$  DNA is that it contains the  $\lambda$  P<sub>L</sub> promoter, N utilization sites L and R (nut<sub>L</sub> and nut<sub>R</sub>) termination RI site (t<sub>RI</sub>), the C<sub>II</sub> ribosomal binding site and an ATG initiation codon. Other features are shown in FIG. 1.

pMG100 was prepared from pKC30. pKC30 in turn was prepared by subcloning of  $\lambda$  P<sub>L</sub> promoter in the following manner.

$\lambda$  phage DNA was digested with *Xho*I and *Sma*I restriction endonucleases and the unique fragment comprised of 6393 base pairs was purified and subsequently digested with *Hind*III and *Bam*HI restriction endonucleases. The resulting



fragment comprised of 2397 base pairs and containing P<sub>L</sub> promoter was purified and ligated into a pBR322 DNA large fragment isolated from the HindIII and BamHI digest. The subclone was identified by colony hybridization, recovered and plasmid DNA isolated (Oppenheim, A. et al., J.Mol.Biol. (1982) 158, 327).

This plasmid and its derivatives containing eukaryotic genes may be maintained in suitable *E. coli* hosts. The most important feature of the host is that it provides the thermosensitive repressor CI857 and the antitermination N protein. (Gottesman, M.E. et al., J.Mol.Biol. (1978) 140, 197).

This vector has numerous advantages over previously described expression vectors including:

### 1. Extremely High Levels of Expression

This vector is capable of directing expression of foreign proteins in *E. coli* at levels as high as 15-25% of the total cellular protein.

### 2. Thermoducible Regulation of Expression

The P<sub>L</sub> promoter is inactive when the CI repressor is bound to it. The CI857 repressor is thermosensitive, that is, it binds to the promoter at 30°C but is inactivated at 42°C. Thus, by increasing the temperature of fermentation to 42°C the host bacteria are induced to produce the desired protein.

The advantages of such a system include the following:

(a) a foreign protein which is toxic to *E. coli* can be produced when desired thus avoiding cell death early in the fermentation process.

(b) overproduction of a protein may stabilize it and prevent proteolytic degradation. (Cheng, Y.E. et al., Gene (1981) 14, 121) Thus, "instantaneous" overproduction using a tightly regulated promoter such as P<sub>L</sub> may be preferable to continuous low level production.

### 3. High Copy Number

The P<sub>L</sub> promoter in pMG100 is found on a plasmid with a high copy number in distinction to  $\lambda$  itself which is present in low copy numbers in *E. coli*. This increases expression levels.

### 4. Ribosome Binding Site and Initiation Codon

This expression vector contains a strong procaryotic ribosomal binding site (RBS) as well as a translation initiation codon (ATG). Thus, any eukaryotic gene may be cloned without the need for adding an initiation codon. Furthermore, the efficient RBS increases levels of expression.

### 5. Convenient Restriction Site

The expression vector has a BamHI site located directly following the ATG initiation codon which permits proper positioning of the desired gene in order to achieve optimal expression.

### 6. Nut Site

N protein which is provided by the host binds to Nut site on the expression vector and thereby prevents termination of transcription at the t<sub>RI</sub> site.

### B. pND5

As shown in FIG. 3, pND5 contains the P<sub>L</sub> promoter and the other important components of the expression vectors of this invention. It includes a unique NdeI site immediately after the ribosomal binding site. The ribosomal binding site differs from the normal C<sub>II</sub> site. It has the sequence:

TAAGGAAGTACTTACAT  
ATTCCTTCATGAATGTA

It may be derived from a mutant or may be chemically synthesized. As described in detail under Description of the Figures pND5 was derived from pOG7. (Oppenheim, A., et al., J.Mol.Biol. (1982) 158, 327) This vector does not contain a translation initiation codon. It appears to provide superior expression of modified bGH and hGH, particularly enhanced yield relative to pMG100 containing a bGH analog.

C. pND55

pND55 is a derivative of pND5 which contains the convenient restriction site SacI in front of C<sub>11</sub>-RBS and ATG initiation codon. Cleavage of the plasmid at this site and subsequent treatment with DNA polymerase Klenow fragment allows one to obtain an ATG initiation codon to which any desired gene can be ligated. (FIG. 3 and Description of FIG. 3.)

II. TRP EXPRESSION VECTORSA. pAL Trp 46

pAL Trp 46 contains the Trp promoter and the first seven amino acids of the Trp E gene fused to the  $\beta$ -galactosidase gene. (FIG. 5). The desired gene can be inserted into a BamHI site which follows the 7 amino acids of Trp E.

B. pAL Trp 47: Trp 46 Deleted of Attenuator

This is a construction based on Trp 46 in which the attenuator region of the Trp promoter has been deleted.

C. Trp-Lac Fusions

The construction of this promoter, found on plasmid p4754 is illustrated in FIGS. 6 and 7. A variation of this construction is outlined in FIG. 8.

III. Histidine Promoter Expression Vectors

The construction of this expression vector is illustrated in FIGS. 9 and 10.

IV. Other Promoters UsedA. Lac

This promoter was used in the construction of pYL 301 as shown in FIG. 11.

B. Omp F

This is a promoter system which expresses a protein attached to a signal sequence. The signal sequence is removed when the protein is translocated across the membrane. (FIG. 12)

EXAMPLE 2Bovine Growth Hormone

The starting point for bGH cDNA modifications is plasmid D<sub>4</sub> which has been described previously. (Keshet, E. et al, Nucleic Acids Research (1981) 9, 19). The D<sub>4</sub> plasmid is also described in pending U.S. patent application, Serial No. 245,943, filed March 20, 1981, claiming priority of Israel patent application, Serial No. 59,690 filed March 24, 1980. It has previously been deposited with the American Type Culture Collection in an E. coli host under ATCC No. 31826.

I. pRec 2/3 bGH

The construction of pRec 2/3 is shown in FIG. 2 and described in the Description of the Figures. bGH cDNA from D<sub>4</sub> has been manipulated prior to insertion into PMG100 to provide the correct reading frame.

pRec 2/3 has been introduced into various E. coli strains including A1637 by transformation using known methods. A1637 containing pRec 2/3 has been deposited under ATCC No. 39385. This strain produces upon growth and induction an analog of bGH having the amino acid sequence Met-Asp-Gln added to the N-terminus of the phenylalanine form of natural bGH. The amount of bGH analog produced by pRec 2/3 was about 23% of the total protein produced by the bacteria as calculated from scanning of Coomassie stained SDS polyacrylamide gels.

II. pROII

The construction of pROII is shown in FIG. 3 and described in the Description of the Figures. The pND5 vector DNA is restricted with NdeI. Insertion of the NdeI fragment from pRec 2/3 (FIG. 2) which contains bGH cDNA results in the plasmid pROII.

pROII has been introduced into *E. coli* A1637 by transformation. The resulting host vector system has been deposited under ATCC No. 39390. This strain when grown and induced produces the same analog as pRec 2/3. Preliminary results indicate that pROII produces up to 20% more bGH analog than pRec 2/3. The methods used to grow the strain, recover the bGH analog produced and purify it are the same as those described for pRec 2/3 in Example 4.

III. pAL401

The construction of pAL401 is shown in FIG. 13 and described in the Description of the Figures. bGH cDNA from D<sub>4</sub> by way of pAL-500 (FIG. 2) was inserted into pND11 as shown in FIG. 13.

pAL401 may be introduced into *E. coli* A1637 by transformation. The resulting strain produces an analog of bGH in which Met<sup>4</sup> of natural bGH is at the N-terminus and the amino acids preceding Met<sup>4</sup> have been deleted.

IV. pAL601

The construction of pAL601 is shown in FIG. 14 and described in the Description of the Figures. It is a derivative of pAL401 (FIG. 13).

pAL601 may be introduced into *E. coli* A1637 by transformation. The resulting strain produces an analog of bGH in which Met has been added to the N-terminus of the phenylalanine form of bGH.

25 EXAMPLE 3Human Growth Hormone

The starting point for hGH cDNA was cloning of the cDNA from mRNA purified from hypophyses tumor from acromegalic patients into the HindIII site of pBR322.

I. pTV 18(1)

The construction of pTV 18(1) is shown in FIG. 4 and described in the Description of the Figures. hGH cDNA was manipulated prior to insertion into pND5 to provide the correct reading frame.

pTV 18(1) was introduced into *E. coli* A1637 by transformation. The resulting bacteria have been deposited under ATCC No. 39386. This strain upon growth and induction produces an analog of hGH having the sequence of natural hGH beginning with Met<sup>14</sup> and lacking amino acids 1-13. The amount of hGH analog produced by pTV 18(1) was about 8% of the total protein produced by the bacteria.

II. pTV 104(2)

The construction of pTV 104(2) is shown in FIG. 4 and described in the Description of the Figures. hGH cDNA was manipulated prior to insertion into pND5 to provide the correct reading frame.

pTV 104(2) was introduced into *E. coli* A1637 by transformation. The resulting bacteria have been deposited under ATCC No. 39384. This strain upon growth and induction produces an analog of hGH having the sequence of natural hGH preceded by Met at the N-terminus. The amount of hGH analog produced by pTV 104(2) was above 25% of the total protein produced by the bacteria.

50 EXAMPLE 4Growth of pRec 2/3

Stock Cultures: Stock cultures of pRec 2/3 in A1637 are grown on BHI medium (see inoculum), then diluted twofold with 87% glycerol containing phosphate citrate buffer, and stored at -70°C.

Inoculum: Inoculum is propagated in BHI medium (37 g/l) brain heart infusion (DIFCO). Sterile medium in shake flask is inoculated from stock culture and incubated 15 hours on shaker at 30°C, 200 r.p.m. Subsequent stages in inoculum propagation are carried out in stirred aerated fermentors. Sterile medium is inoculated with 0.2 ml flask culture per

# EP 0 691 406 A1

1, and incubated 15 hours at 30°C, pH 7 $\pm$  0.5 with agitation and aeration to maintain dissolved oxygen level above 20% air saturation.

Production: Production medium contains:

|                                     |          |
|-------------------------------------|----------|
| Lactalbumin hydrolysate (enzymatic) | 20 g/l   |
| Yeast extract                       | 10 g/l   |
| K <sub>2</sub> HPO <sub>4</sub>     | 2.5 g/l  |
| NaCl                                | 10 g/l   |
| Ampicillin                          | 0.1 g/l  |
| Biotin                              | 0.1 mg/l |
| Thiamine                            | 1 mg/l   |
| Trace elements solution             | 3 ml/l   |

Ampicillin, biotin and thiamine in solution are filter sterilized separately and added to the sterile production medium before inoculation. Sterile glucose solution is added initially to supply 10 g/l, and during the induction and expression procedure to maintain glucose above 10 g/l

Trace elements solution contains:

|   |          |
|---|----------|
| MgSO <sub>4</sub> ·7H <sub>2</sub> O                | 170 g/l  |
| FeCl <sub>3</sub>                                   | 16 g/l   |
| ZnCl <sub>2</sub> ·4H <sub>2</sub> O                | 2 g/l    |
| CoCl <sub>2</sub> ·6H <sub>2</sub> O                | 2 g/l    |
| Na <sub>2</sub> MoO <sub>4</sub> ·2H <sub>2</sub> O | 2 g/l    |
| CaCl <sub>2</sub> ·2H <sub>2</sub> O                | 1 g/l    |
| CuCl <sub>2</sub>                                   | 1 g/l    |
| H <sub>3</sub> BO <sub>3</sub>                      | 0.5 g/l  |
| Conc. HCl   | 100 ml/l |

The medium is inoculated with 5-10% inoculum culture and incubated at 30°C. Agitation-aeration rates are set to maintain dissolved oxygen level above 20% air saturation. The pH is maintained at 7 $\pm$ 0.2 with NH<sub>3</sub>. Once cell concentration reaches about 3 g/l (OD<sub>660</sub> = 10) induction is started.

Temperature is raised to 42°C. Maintained there for 15 minutes, then lowered to 38°C. Following incubation at 38°C for 1-1 1/2 hours, the culture is chilled, and cells are recovered by centrifugation for hormone purification.

## Recovery of bGH

One kilogram of bacterial cells is suspended in 10 volumes of the solution containing 50 mM Tris-Cl (pH 7.4), 50 mM EDTA and 25% sucrose in a Warring blender, with a control of blender's speed to minimize foaming. The homogeneous suspension is continuously passed through a Dymomill cell disruptor (Willy A. Bachofen, Basel) and the homogeneous suspension of disrupted cells is clarified first by centrifugation in a Sharpless centrifuge followed by a continuous centrifugation at 20,000 rpm in a Sorvall centrifuge. The precipitate from both centrifugation steps is collected, washed with 50 mM Tris-Cl (pH 7.4) and resuspended in 500 ml of the same buffer. Lysozyme is added to a final concentration of 2 mg/ml and the suspension is incubated for 1 hour at 37°C. Triton X-100 is then added to a final concentration of 1%, the suspension is cooled to 4°C and centrifuged at 20,000 rpm for 20 minutes in a Sorvall SS34 rotor. The precipitate is collected, washed twice with 50 mM Tris-Cl, resuspended in 500 ml of 50 mM Tris-Cl (pH 7.4), 5 mM MgCl<sub>2</sub> and deoxyribonuclease is added to a final concentration of 20  $\mu$ g/ml. After incubation for 30 minutes at room temperature

the precipitate is collected as above, washed twice with 500 ml of 20 mM Tris-Cl (pH 7.4), 100 mM NaCl and 10 mM EDTA, followed by two washings with 500 ml of distilled water. The precipitate is collected by centrifugation and can be stored at -20°C for an indefinite time. At this stage the bGH is 80% pure as judged by sodium dodecyl sulfate-gel electrophoresis. The yield is approximately 15 g of bGH.

#### Purification of bGH

One hundred gr of precipitate is suspended in 40 ml distilled water and solubilized by titration with 0.5 M NaOH, pH 11.8. The solution is then sonicated for 2 minutes and clarified by centrifugation at 20,000 rpm in a Sorvall SS34 rotor for 20 minutes. The solution is then applied onto a Sepharose CL-6B column (5 x 100 cm) equilibrated with 6.5 mM borate buffer, pH 11.8. Column is developed at the rate of 100 ml/hr and fractions of 12 ml are collected. The first peak off the column is discarded. The following two peaks are separated and pooled. The first represents aggregated bGH with low activity; the second bGH with high activity.

A DEAE-Sephacel (25 g/100 gr. equiv. ppt) column is equilibrated with 6.5 mM borate buffer, pH 9.0. The second bGH peak is brought to pH 9.0 with HCl loaded on the DEAE Sephacel column at a rate of 250 ml/hr. The column is washed with 7.5 ml of 6.5 mM borate buffer, pH 9.0, eluted with 6.5 mM borate buffer, pH 9.0 containing 75 mM NaCl. The fractions with OD<sub>280</sub> above 0.3 are pooled, dialysed against H<sub>2</sub>O in Millipore Pellicon dialysis apparatus and then lyophilized.

#### EXAMPLE 5

##### Activity of bGH Analog Produced by pRec 2/3

##### 1. Radioimmunoassay comparison of bGH analog with natural bGH

A solution containing 100 ng/ml bGH analog was prepared in phosphate buffered saline (1% BSA). This solution was diluted serially to concentrations of 50, 25, 12.5, 6.25, 3.12, 1.56 and 0.78 ng/l. Duplicate 0.1 ml aliquots of these solutions were submitted to RIA using a double antibody procedure. The dilution curve was comparable to that obtained with natural bGH.

##### 2. Radioreceptor binding Assay

A radioreceptor binding assay was performed with rabbit liver membranes as described by T. Tushima and H.G. Freisen (Y. Chin., Endocr. Metab. (1973) 37, 334 using <sup>125</sup>I-hGH as the tracer and authentic bGH solutions for the construction of calibration curves. Samples were incubated in triplicate for two hours at room temperature in 0.3 ml of assay buffer (50 mM Tris, 15 mM CaCl<sub>2</sub> and 5 mg/ml bovine serum albumin, pH 7.6). The tubes contained <sup>125</sup>I-hGH (20,000 cpm of preparation of 30-60 µCi/µg), 150-250 µg liver membrane protein and either natural bGH (1-100 ng) or extracts of bacterial bGH. The result demonstrated that the bGH activity of the bGH analog is comparable to that of natural bGH.

##### 3. Tibia Test

The bioactivity of the pRec 2/3 bGH analog recovered from engineering bacterial cells according to Example 4 was evaluated by a tibia test. (Parlow, A.F., et al., Endocrinology (1965) 77, 1126.)

Rats were hypophysectomized at 28-30 days of age, then kept for 10-14 days without treatment. Bovine growth hormone derived from bovine pituitaries or from recombinant *E. coli* was dissolved in 0.15M NaCl + 0.01 M borate, pH 10.0. Rats (4-7 per group) received daily subcutaneous injections of bGH solutions (5-125 µg/day in 0.2 cc) for 5 days while kept on a normal diet (Purina Rat-Chow and water *ad libitum*). The animals were sacrificed on the 6th day, their foreleg knee-bones taken out, cut longitudinally, fixed with acetone and stained with 2% AgNO<sub>3</sub>. The width of the epiphyseal plates were measured by observation through a dissecting binocular (Nikon). Mean values (of 40 readings per rat) were used for the construction of log dose-response curves. Results are shown in FIG. 15.

EXAMPLE 6bGH Analogs

Table I sets forth a series of plasmids which have been constructed and the analogs which were produced from them.

TABLE I

| PLASMID   | AMINO TERMINUS OF bGH ANALOGS              |
|-----------|--|
| Rec 2/3   | Met Asp Gln Phe <sup>2</sup>               |
| pB 1      | Met Asp Pro Met Gly Ala Phe <sup>2</sup>   |
| pM 4      | Met Asp Pro Phe <sup>2</sup>               |
| pM 1      | Met Ala <sup>1</sup> Phe <sup>2</sup>      |
| pM 2      | Met Ala <sup>1</sup> Phe <sup>2</sup>      |
| pAL 401   | Met <sup>4</sup>                           |
| pYL 301   | Met Gly Ala <sup>1</sup> Phe <sup>2</sup>  |
| pAL 302   | 11 A.A + Ala <sup>1</sup> Phe <sup>2</sup> |
| pHis 129  | Met Thr Arg Phe <sup>2</sup>               |
| pAL 312   | Met Gly Ala <sup>1</sup> Phe <sup>2</sup>  |
| pAL 322   | Met Gly Ala <sup>1</sup> Phe <sup>2</sup>  |
| pAL 601R  | Met Gly Ala <sup>1</sup> Phe <sup>2</sup>  |
| p 18      | Met Gly Ala <sup>1</sup> Phe <sup>2</sup>  |
| PBTG-800  | Met Glu Phe <sup>2</sup>                   |
| pORF 2-12 | Ala Gly Ala <sup>1</sup> Phe <sup>2</sup>  |

EXAMPLE 7Effect of pRec 2/3 bGH analog on Lactogenesis in Dairy Cows

The lactogenic effect of bGH has been well documented in the scientific literature in the reports of Bines, J. et al, Brit J. Nutri. (1980) 43, 179 and Peel, C. et al, J. Nutr. (1981) 111, 1662. Bauman, D. et al, J. Dairy Sci. Vol. Supp. 1, Abst 86 (1982) reported that milk production was increased by rDNA bGH. An experiment was conducted to determine the effects of pRec 2/3 bGH on lactogenesis in comparison with natural bGH. Eighteen Holstein cows ranging from 141 to 154 days postpartum were randomly assigned to treatment and blocked according to milk production according to the following design.

| Pretreatment | Treatment | Daily GH Injection    |
|--------------|-----------|-----------------------|
| Control      | 5 days    | Saline                |
| Natural bGH  | 5 days    | 25 mg/day for 10 days |
| pRec 2/3 bGH | 5 days    | 25 mg/day for 10 days |

The bGHs were put in solution with 0.1 M NaHCO<sub>3</sub> aqueous buffer (pH = 8.2) at the concentration of 1 mg/ml immediately prior to each day's injections. The cows were injected with placebo or bGH solution daily for 10 days in a subcutaneous site in the neck region. No injections were given during the 5-day pretreatment period.

The cows were milked twice daily at approximately 6:00 a.m. and 5:00 p.m. Milk weights were recorded by the Boumatic system and recorded in the dairy data system.

The average milk production values for the pretreatment and bGH treatment periods are shown in Table II. The production level of the control cows was unchanged while the milk volume increased to a similar degree in both the bGH groups. The natural bGH caused an 11.9% increase in milk for a 10-day period and bGH analog treatment resulted in a 10.2% increase. The data were not analyzed for statistical significance due to the small number of animals, however, the magnitudes of the increases are similar to those reported in the literature.

It was concluded that pRec 2/3 bGH stimulates lactogenesis in dairy cows similar to natural bGH.

TABLE II

| Bovine Growth Hormone Effect on Lactogenesis Natural bGH vs pRec 2/3 bGH |     |                                  |                   |                              |
|--|-----|----------------------------------|-------------------|------------------------------|
| Treatment Group  | No. | Av. Daily Milk Production lb/day |                   |                              |
|  |     | Pretreatment 5 days              | During GH 10 days | % Increase Over Pretreatment |
| Control  | 6   | 57.23                            | 57.26             | -                            |
| Natural bGH 25 mg/day  | 5   | 58.54                            | 65.50             | 11.9                         |
| pRec 2/3 bGH 25 mg/day   | 6   | 57.48                            | 63.34             | 10.2                         |

Each cow was injected daily subcutaneously with either placebo or bGH solution once daily for 10 days.

#### Claims

1. An improved plasmid which upon introduction into a suitable *Escherichia coli* host cell containing the thermolabile repressor  $C_{17}$ , renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a gene encoding superoxide dismutase inserted into the vector, and production of the superoxide dismutase encoded by the gene comprising:
  - a double-stranded DNA molecule which comprises in 5' to 3' order the following:
    - a DNA sequence which contains the promoter and operator  $P_{L}O_L$  from lambda bacteriophage;
    - an N utilization site for binding antiterminator N protein produced by the host cell;
    - a DNA sequence which contains a ribosomal binding site for rendering the mRNA of the gene encoding superoxide dismutase capable of binding to ribosomes within the host cell;
    - an ATG initiation codon or a DNA sequence which is converted into an ATG initiation codon upon insertion of the gene encoding superoxide dismutase into the vector;
    - a gene encoding superoxide dismutase inserted into a restriction enzyme site in phase with the ATG initiation codon; and which additionally includes a DNA sequence which contains an origin of replication from a bacterial plasmid capable of autonomous replication in the host cell and a DNA sequence which contains a gene associated with a selectable or identifiable phenotypic trait which is manifested when the vector is present in the host cell.
2. A host-vector system for production of superoxide dismutase comprising the plasmid of claim 1 in a host suitable for production of superoxide dismutase.
3. A host-vector system of claim 2 wherein the host is *Escherichia coli* strain A1637 (ATCC Accession No. 39385 containing plasmid pRec 2/3) or *Escherichia coli* strain A1645.
4. A method of producing superoxide dismutase which comprises growing the host vector system of claim 2 under suitable conditions permitting production of superoxide dismutase and recovering the resulting superoxide dismutase.

FIG.1.






FIG. 2.




FIG.3.




FIG 4.




FIG.5.

SUBCLONING OF TRP PROMOTER  
WITH LEADER, ATTENUATOR AND  
25 BP OF E GENE




FIG. 6.  
CONSTRUCTION OF *Tac* PROMOTER





FIG. 7.



Trp-35region  
Lac-40region } TAC Promoter

-----CACACAGGAACAGGAT'CCT ATG GGC GCCTTC

S.D.

FIG.8.

CLONING OF bGH INTO A Trp-Lac  
FUSED PROMOTER PLASMID





FIG. 9.


EXPRESSION OF bGH WITH His PROMOTER



FIG.10.




FIG11.

HAE II FRAGMENT WITH SYNTHETIC  
LINKER pYL-301




FIG. 12.




FIG.13.




FIG.14.





FIG.15.

EFFECT OF PITUITARY-DERIVED AND RECOMBINANT  
BOVINE GROWTH HORMONE ON BONE PLATE GROWTH  
AFTER 5 DAYS OF SUBCUTANEOUS INJECTION TO  
HYPOPHYSECTOMIZED RATS





European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 95 11 4069

| DOCUMENTS CONSIDERED TO BE RELEVANT  |   |                                  |  |
|--|---|----------------------------------|--|
| Category   | Citation of document with indication, where appropriate, of relevant passages   | Relevant to claim                | CLASSIFICATION OF THE APPLICATION (Int.Cl.4) |
| A  | EP-A-0 041 767 (BIOGEN) 16 December 1981<br>* the whole document *<br>---   | 1                                | C12N15/53<br>C12N15/73<br>C12N9/02           |
| A  | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 79, May 1982 WASHINGTON US, pages 2808-2811, J LIEMAN-HURWITZ 'Human cytoplasmic superoxide dismutase cDNA clone: A probe for studying the molecular biology of Down syndrome.'<br>* the whole document *<br>----- | 1                                |  |
|  |   |                                  | TECHNICAL FIELDS SEARCHED (Int.Cl.4)         |
|  |   |                                  | C12N   |
| The present search report has been drawn up for all claims   |   |                                  |  |
| Place of search  |   | Date of completion of the search | Examiner                                     |
| THE HAGUE  |   | 16 October 1995                  | Delanghe, L                                  |
| <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone<br/>Y : particularly relevant if combined with another document of the same category<br/>A : technological background<br/>O : non-written disclosure<br/>P : intermediate document</p> <p>T : theory or principle underlying the invention<br/>E : earlier patent document, but published on, or after the filing date<br/>D : document cited in the application<br/>L : document cited for other reasons</p> <p>Δ : member of the same patent family, corresponding document</p> |   |                                  |  |

EPF FORM 1501 (04/95) (P/0001)